Oral Antidiabetic Drugs Global Market Report 2025

Description

Oral antidiabetic drugs are medications taken orally to help regulate and control blood sugar levels in people with type 2 diabetes. These drugs act through different mechanisms, including enhancing insulin sensitivity, promoting insulin secretion, or decreasing glucose production in the liver. They play a crucial role in diabetes management to prevent complications and support long-term health.

The primary classes of oral antidiabetic drugs include biguanides, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, among others. Biguanides specifically lower blood glucose mainly by reducing liver glucose production and increasing insulin sensitivity. These medications can be administered orally, sublingually, or buccally, and are used to treat conditions such as type 2 diabetes, gestational diabetes, and type 1 diabetes. They are distributed through various channels including hospital pharmacies, retail pharmacies, online pharmacies, and more, with key end users comprising hospitals, pharmacy stores, drugstores, diabetes treatment centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The oral antidiabetic drugs market research report is one of a series of new reports from The Business Research Company that provides oral antidiabetic drugs market statistics, including the oral antidiabetic drugs industry global market size, regional shares, competitors with the oral antidiabetic drugs market share, detailed oral antidiabetic drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the oral antidiabetic drugs industry. This oral antidiabetic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The oral antidiabetic drug market size has grown strongly in recent years. It will grow from $62.25 billion in 2024 to $66.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth during the historic period can be attributed to the rising prevalence of diabetes, growing awareness of diabetes management, an expanding elderly population, increased availability of advanced oral antidiabetic formulations, and the development of healthcare infrastructure.

The oral antidiabetic drugs market size is expected to see strong growth in the next few years. It will grow to $86.92 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The anticipated growth in the forecast period can be linked to the growing adoption of novel oral antidiabetic therapies, increased investments in diabetes research and development, rising demand for affordable diabetes treatments, the global surge in type 2 diabetes prevalence, and a stronger emphasis on personalized medicine in diabetes care. Key trends expected during this time include advancements in drug delivery technologies, innovations in combination therapies, incorporation of digital health tools for diabetes management, development of safer and more effective oral antidiabetic drugs, and progress in personalized treatment strategies.

The rising incidence of type 2 diabetes is expected to drive the growth of the oral antidiabetic drugs market in the coming years. Type 2 diabetes is a chronic condition characterized by the body's resistance to insulin or insufficient insulin production needed to regulate normal blood glucose levels. The increase in type 2 diabetes cases is largely due to rising obesity rates, as excess body fat leads to insulin resistance and disrupted glucose metabolism. Oral antidiabetic drugs help manage type 2 diabetes by improving insulin sensitivity, boosting insulin secretion, or decreasing glucose production and absorption, thereby maintaining healthy blood sugar levels. For example, in March 2025, the Office for Health Improvement and Disparities, a UK government agency, reported that the prevalence of type 2 diabetes among adults aged 17 and older in England rose to 7.0%, up from 6.8% in March 2023. Consequently, the growing prevalence of type 2 diabetes is fueling the expansion of the oral antidiabetic drugs market.

Key players in the oral antidiabetic drugs market are focusing on clinical trials to develop safer and more effective treatments, expand their product lines, and secure regulatory approvals for next-generation therapies. Clinical trials are controlled studies involving human participants to assess the safety, efficacy, and side effects of new drugs or medical interventions. For instance, in April 2025, Eli Lilly and Company, a US-based pharmaceutical firm, launched Orforglipron, a once-daily oral small-molecule GLP-1 receptor agonist designed to simplify diabetes management, following a successful phase 3 trial. This oral medication aims to provide similar efficacy and safety to injectable therapies while improving patient compliance. In clinical trials, Orforglipron reduced HbA1c levels (a measure of blood sugar control) by an average of 1.3% to 1.6% across various doses over 40 weeks.

In January 2024, Roche Group, a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics Inc. for an undisclosed sum. This acquisition was intended to strengthen Roche's pipeline in obesity and diabetes treatments by gaining access to Carmot Therapeutics' innovative small-molecule drugs targeting incretin biology. Carmot Therapeutics, based in the US, is developing oral antidiabetic drugs including CT-996, a once-daily oral small-molecule GLP-1 receptor agonist.

Major players in the oral antidiabetic drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, C.H. Boehringer Sohn AG & Co. KG, Viatris Inc., Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Cipla Limited.

North America was the largest region in the oral antidiabetic drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in oral antidiabetic drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the oral antidiabetic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oral antidiabetic drugs market consists of sales of dual or combination oral therapies, glucokinase activators, and amylin analogs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oral Antidiabetic Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on oral antidiabetic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oral antidiabetic drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oral antidiabetic drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Biguanides; Dipeptidyl Peptidase-4 Inhibitors; Sodium Glucose Transport Protein -2 Inhibitors; Sulfonylureas; Thiazolidinediones; Megalitinides; Alpha Glucosidase Inhibitors; Other Drug Classes
2) By Route Of Administration: Oral; Sublingual; Buccal
3) By Therapeutic Area: Type 2 Diabetes; Gestational Diabetes; Type 1 Diabetes
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Channels
5) By End User: Hospitals; Pharmact Store; Drug Store; Diabetes Treatment Centers; Other End Users
Subsegments:
1) By Biguanides: Metformin Hydrochloride; Metformin Extended Release; Combination Products
2) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin; Vildagliptin
3) By Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin
4) By Sulfonylureas: Glipizide; Glyburide; Glimepiride; Chlorpropamide; Tolbutamide
5) By Thiazolidinediones: Pioglitazone; Rosiglitazone
6) By Meglitinides: Repaglinide; Nateglinide
7) By Alpha Glucosidase Inhibitors: Acarbose; Miglitol; Voglibose
8) By Other Drug Classes: Bromocriptine; Colesevelam
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Bayer AG; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Novo Nordisk A/S; C.H. Boehringer Sohn AG & Co. KG; Viatris Inc.; Teva Pharmaceutical Industries Limited; Astellas Pharma Inc.; Sun Pharmaceutical Industries Limited; Cipla Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37083

1. Executive Summary

2. Oral Antidiabetic Drugs Market Characteristics

3. Oral Antidiabetic Drugs Market Trends And Strategies

4. Oral Antidiabetic Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Oral Antidiabetic Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Oral Antidiabetic Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Oral Antidiabetic Drugs Market Growth Rate Analysis
5.4. Global Oral Antidiabetic Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Oral Antidiabetic Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Oral Antidiabetic Drugs Total Addressable Market (TAM)

6. Oral Antidiabetic Drugs Market Segmentation

6.1. Global Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biguanides
Dipeptidyl Peptidase-4 Inhibitors
Sodium Glucose Transport Protein -2 Inhibitors
Sulfonylureas
Thiazolidinediones
Megalitinides
Alpha Glucosidase Inhibitors
Other Drug Classes
6.2. Global Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Sublingual
Buccal
6.3. Global Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Type 2 Diabetes
Gestational Diabetes
Type 1 Diabetes
6.4. Global Oral Antidiabetic Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Channels
6.5. Global Oral Antidiabetic Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Pharmact Store
Drug Store
Diabetes Treatment Centers
Other End Users
6.6. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metformin Hydrochloride
Metformin Extended Release
Combination Products
6.7. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
Vildagliptin
6.8. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Sodium Glucose Transport Protein-2 (SGLT2) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Canagliflozin
Dapagliflozin
Empagliflozin
Ertugliflozin
6.9. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Glipizide
Glyburide
Glimepiride
Chlorpropamide
Tolbutamide
6.10. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pioglitazone
Rosiglitazone
6.11. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Meglitinides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Repaglinide
Nateglinide
6.12. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Alpha Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acarbose
Miglitol
Voglibose
6.13. Global Oral Antidiabetic Drugs Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bromocriptine
Colesevelam

7. Oral Antidiabetic Drugs Market Regional And Country Analysis

7.1. Global Oral Antidiabetic Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Oral Antidiabetic Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oral Antidiabetic Drugs Market

8.1. Asia-Pacific Oral Antidiabetic Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oral Antidiabetic Drugs Market

9.1. China Oral Antidiabetic Drugs Market Overview
9.2. China Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oral Antidiabetic Drugs Market

10.1. India Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oral Antidiabetic Drugs Market

11.1. Japan Oral Antidiabetic Drugs Market Overview
11.2. Japan Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oral Antidiabetic Drugs Market

12.1. Australia Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oral Antidiabetic Drugs Market

13.1. Indonesia Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oral Antidiabetic Drugs Market

14.1. South Korea Oral Antidiabetic Drugs Market Overview
14.2. South Korea Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oral Antidiabetic Drugs Market

15.1. Western Europe Oral Antidiabetic Drugs Market Overview
15.2. Western Europe Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oral Antidiabetic Drugs Market

16.1. UK Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oral Antidiabetic Drugs Market

17.1. Germany Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oral Antidiabetic Drugs Market

18.1. France Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oral Antidiabetic Drugs Market

19.1. Italy Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oral Antidiabetic Drugs Market

20.1. Spain Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oral Antidiabetic Drugs Market

21.1. Eastern Europe Oral Antidiabetic Drugs Market Overview
21.2. Eastern Europe Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oral Antidiabetic Drugs Market

22.1. Russia Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oral Antidiabetic Drugs Market

23.1. North America Oral Antidiabetic Drugs Market Overview
23.2. North America Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oral Antidiabetic Drugs Market

24.1. USA Oral Antidiabetic Drugs Market Overview
24.2. USA Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oral Antidiabetic Drugs Market

25.1. Canada Oral Antidiabetic Drugs Market Overview
25.2. Canada Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oral Antidiabetic Drugs Market

26.1. South America Oral Antidiabetic Drugs Market Overview
26.2. South America Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oral Antidiabetic Drugs Market

27.1. Brazil Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oral Antidiabetic Drugs Market

28.1. Middle East Oral Antidiabetic Drugs Market Overview
28.2. Middle East Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oral Antidiabetic Drugs Market

29.1. Africa Oral Antidiabetic Drugs Market Overview
29.2. Africa Oral Antidiabetic Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Oral Antidiabetic Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Oral Antidiabetic Drugs Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oral Antidiabetic Drugs Market Competitive Landscape And Company Profiles

30.1. Oral Antidiabetic Drugs Market Competitive Landscape
30.2. Oral Antidiabetic Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Oral Antidiabetic Drugs Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Sanofi S.A.
31.3. Bristol-Myers Squibb Company
31.4. AstraZeneca plc
31.5. Abbott Laboratories
31.6. GlaxoSmithKline plc
31.7. Takeda Pharmaceutical Company Limited
31.8. Eli Lilly and Company
31.9. Novo Nordisk A/S
31.10. C.H. Boehringer Sohn AG & Co. KG
31.11. Viatris Inc.
31.12. Teva Pharmaceutical Industries Limited
31.13. Astellas Pharma Inc.
31.14. Sun Pharmaceutical Industries Limited
31.15. Cipla Limited

32. Global Oral Antidiabetic Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oral Antidiabetic Drugs Market

34. Recent Developments In The Oral Antidiabetic Drugs Market

35. Oral Antidiabetic Drugs Market High Potential Countries, Segments and Strategies

35.1 Oral Antidiabetic Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Oral Antidiabetic Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Oral Antidiabetic Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer